De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
HealthEquity Beheer
Beheer criteriumcontroles 3/4
De CEO HealthEquity's is Jon Kessler, benoemd in Feb2014, heeft een ambtstermijn van 10.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.45M, bestaande uit 5.2% salaris en 94.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde $ 25.02M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 7.6 jaar.
Belangrijke informatie
Jon Kessler
Algemeen directeur
US$13.4m
Totale compensatie
| Percentage CEO-salaris | 5.2% |
| Dienstverband CEO | 10.7yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 7.6yrs |
Recente managementupdates
Recent updates
Getting In Cheap On HealthEquity, Inc. (NASDAQ:HQY) Might Be Difficult
Aug 30
HealthEquity: Compelling Catalysts, Fairly Valued, Reiterate Buy
Aug 27Is HealthEquity (NASDAQ:HQY) Using Too Much Debt?
Jul 13We Think Some Shareholders May Hesitate To Increase HealthEquity, Inc.'s (NASDAQ:HQY) CEO Compensation
Jun 21Earnings Beat: HealthEquity, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jun 07HealthEquity: A Trading Vehicle Performing As Expected, Strong Growth Hard To Ignore
Jun 04HealthEquity: Strong Growth And Healthy Cash Flows Changed My Mind
May 29Are Investors Undervaluing HealthEquity, Inc. (NASDAQ:HQY) By 48%?
May 03Market Participants Recognise HealthEquity, Inc.'s (NASDAQ:HQY) Revenues
Apr 11HealthEquity: Multiple Compression Has Finally Made It A Buy
Mar 21Investors Appear Satisfied With HealthEquity, Inc.'s (NASDAQ:HQY) Prospects
Dec 28Is HealthEquity (NASDAQ:HQY) A Risky Investment?
Nov 17HealthEquity, Inc.'s (NASDAQ:HQY) Intrinsic Value Is Potentially 51% Above Its Share Price
Oct 26Does HealthEquity (NASDAQ:HQY) Have A Healthy Balance Sheet?
Jul 27HealthEquity, Inc. (NASDAQ:HQY) Shares Could Be 37% Below Their Intrinsic Value Estimate
Jul 07Does HealthEquity (NASDAQ:HQY) Have A Healthy Balance Sheet?
Apr 18Estimating The Intrinsic Value Of HealthEquity, Inc. (NASDAQ:HQY)
Mar 14Is HealthEquity (NASDAQ:HQY) Using Too Much Debt?
Dec 24Is Now An Opportune Moment To Examine HealthEquity, Inc. (NASDAQ:HQY)?
Dec 02Is HealthEquity, Inc. (NASDAQ:HQY) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 11These 4 Measures Indicate That HealthEquity (NASDAQ:HQY) Is Using Debt Extensively
Sep 08HealthEquity Non-GAAP EPS of $0.33 in-line, revenue of $206.1M beats by $2.22M
Sep 06HealthEquity: Asymmetry In Valuation Continues To Widen
Aug 25HealthEquity COO steps down, CEO to assume his responsibilities
Aug 02Is Now An Opportune Moment To Examine HealthEquity, Inc. (NASDAQ:HQY)?
Jul 27Calculating The Intrinsic Value Of HealthEquity, Inc. (NASDAQ:HQY)
Jul 06These 4 Measures Indicate That HealthEquity (NASDAQ:HQY) Is Using Debt Extensively
May 24Is Now An Opportune Moment To Examine HealthEquity, Inc. (NASDAQ:HQY)?
Apr 12An Intrinsic Calculation For HealthEquity, Inc. (NASDAQ:HQY) Suggests It's 29% Undervalued
Mar 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | US$106m |
| Apr 30 2024 | n/a | n/a | US$80m |
| Jan 31 2024 | US$13m | US$700k | US$56m |
| Oct 31 2023 | n/a | n/a | US$29m |
| Jul 31 2023 | n/a | n/a | US$13m |
| Apr 30 2023 | n/a | n/a | -US$8m |
| Jan 31 2023 | US$13m | US$700k | -US$26m |
| Oct 31 2022 | n/a | n/a | -US$59m |
| Jul 31 2022 | n/a | n/a | -US$62m |
| Apr 30 2022 | n/a | n/a | -US$55m |
| Jan 31 2022 | US$10m | US$700k | -US$44m |
| Oct 31 2021 | n/a | n/a | -US$6m |
| Jul 31 2021 | n/a | n/a | US$723k |
| Apr 30 2021 | n/a | n/a | US$4m |
| Jan 31 2021 | US$9m | US$667k | US$9m |
| Oct 31 2020 | n/a | n/a | US$3m |
| Jul 31 2020 | n/a | n/a | -US$20m |
| Apr 30 2020 | n/a | n/a | -US$332k |
| Jan 31 2020 | US$5m | US$500k | US$40m |
| Oct 31 2019 | n/a | n/a | US$53m |
| Jul 31 2019 | n/a | n/a | US$90m |
| Apr 30 2019 | n/a | n/a | US$93m |
| Jan 31 2019 | US$5m | US$483k | US$74m |
| Oct 31 2018 | n/a | n/a | US$67m |
| Jul 31 2018 | n/a | n/a | US$61m |
| Apr 30 2018 | n/a | n/a | US$56m |
| Jan 31 2018 | US$4m | US$400k | US$47m |
Compensatie versus markt: De totale vergoeding ($USD 13.45M ) Jon } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).
Compensatie versus inkomsten: De vergoeding van Jon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jon Kessler (56 yo)
10.7yrs
Tenure
US$13,448,018
Compensatie
Mr. Jon Kessler is a Member of the Board of Managers at HealthEquity Advisors, LLC. He has been the Chief Executive Officer and President of HealthEquity, Inc. since February 2014. Mr. Kessler founded Wage...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10.7yrs | US$13.45m | 0.35% $ 25.4m | |
| Founder & Vice Chairman | 21.9yrs | US$3.04m | 0.94% $ 68.5m | |
| CFO & Executive VP | 1.1yrs | US$5.23m | 0.011% $ 772.7k | |
| Executive VP & CTO | 2.6yrs | US$4.81m | 0% $ 0 | |
| Executive VP | 8.1yrs | US$2.64m | 0.043% $ 3.2m | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Sales & Relationship Management | 3.2yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Corporate Development & Strategy | 7.5yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Marketing Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief People Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Senior VP & Head of Product | 1.9yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Security Officer | no data | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HQY wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 15.6yrs | US$13.45m | 0.35% $ 25.4m | |
| Founder & Vice Chairman | 21.9yrs | US$3.04m | 0.94% $ 68.5m | |
| Independent Director | 8.1yrs | US$297.50k | 0.062% $ 4.5m | |
| Independent Non-Executive Chairman | 9.1yrs | US$362.50k | 0.052% $ 3.8m | |
| Independent Director | 2.1yrs | US$272.50k | 0.0050% $ 365.0k | |
| Independent Director | 10.2yrs | US$290.00k | 0.037% $ 2.7m | |
| Independent Director | 3.8yrs | US$280.00k | 0.035% $ 2.5m | |
| Independent Director | 7.2yrs | US$278.87k | 0.017% $ 1.3m | |
| Independent Director | 6.5yrs | US$275.00k | 0.012% $ 850.4k | |
| Independent Director | 2.4yrs | US$272.50k | 0.0096% $ 698.0k |
7.6yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HQY wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).